Conference Track

Clinical Complications in HIV-Infected Patients

Source: CCO Official Conference Coverage of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention

Capsule Summaries

Screening for HLA-B*5701 Sensitive and Specific for Detecting Abacavir Hypersensitivity in White and Black Patients
Long-term Glucose Tolerance Stable With Lopinavir/Ritonavir or Efavirenz
Hepatitis Coinfection in Patients Undergoing Structured Treatment Interruptions Further Elevates Risk of Death
HCV Genomic Analysis Demonstrates International HCV Transmission by Sexual Contact in HIV-Positive MSM in Europe
No Evidence of Increased Subclinical Atherosclerosis in Patients on Sustained HAART
Fosamprenavir Boosted With Ritonavir 100 mg Virologically Effective and Tolerable in Treatment-Naive Patients
Low Mortality Found Among HIV-Infected Patients Simultaneously Treated With Antiretrovirals and Antituberculosis Therapy
High Prevalence of Renal Impairment Among HIV-Infected Individuals: Several Risk Factors Identified
Initiating Rifampicin When Starting Efavirenz-Based HAART Does Not Diminish Antiviral Response in HIV-1/TB–Coinfected Patients
New Blood Marker-Based Test Appears to More Accurately Determine HCV-Related Fibrosis in HIV/HCV-Coinfected Patients
Hepatitis Coinfection in Patients Undergoing Structured Treatment Interruptions Further Elevates Risk of Death
Single-Agent HBV Antiviral Therapy With Tenofovir or Lamivudine Similar in Efficacy as Combination at Week 48 in HIV/HBV-Coinfected Patients
Prolonged Impairment in Glucose Metabolism Associated With Zidovudine/Lamivudine-Containing Regimen, With Onset Preceding Body Composition Changes
HBV—but Not HCV—Coinfection a Significant Predictor of ART Reinitiation in the SMART Study of HIV-Infected Patients
Tipranavir-Containing Regimens Not Associated With Lipodystrophy or Insulin Resistance Over 48 Weeks
Suppression of HIV-1 RNA May Be More Important Than Initial ART Regimen in Preventing Cardiovascular Complications
PREDICT-1: HLA-B*5701 Allele Screening Reduces Incidence of Abacavir Hypersensitivity

Expert Analysis

Clinical Complications in HIV-Infected Patients

Faculty:

Andrew Carr, MBBS, MD, FRACP
Donald P. Kotler, MD
Jürgen K. Rockstroh, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe data on the use of a genotype test to identify patients who are at increased risk of abacavir hypersensitivity reactions
Discuss data that indicate a sexual transmission route for hepatitis C virus
Summarize data about metabolic effects of antiretroviral therapy

CREDIT INFORMATION

Release Date: September 28, 2007

Expiration Date: September 27, 2008

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.3 Nursing contact hours

Pharmacists: 1.3 contact hours (0.13 CEUs)

Status: The activity is not currently available for credit.

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.